Analysis of 1-methyladenosine for a biomarker in patients with diffuse large B-cell lymphoma.

Analysis of 1-methyladenosine for a biomarker in patients with diffuse large B-cell lymphoma. - m1A in DLBCL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020756

Enrollment

Registered

2016-01-28

Start date

2016-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diffuse large B-cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: DLBCL cases who are treated by R-CHOP or R-THP-COP chemotherapy in Kanazawa Medical University.

Exclusion criteria

Exclusion criteria: DLBCL cases who are treated by other chemotherapy regimen.

Design outcomes

Primary

Measure	Time frame
correlation of plasma m1A concentration and curative effect after chemotherapy	—

Secondary

Measure	Time frame
correlation of urinary m1A concentration and curative effect after chemotherapy	—

Countries

Japan

Contacts

Public ContactYasufumi Masaki

Kanazawa Medical University Division of Hematology and Immunology

yasum@kanazawa-med.ac.jp076-286-3511

Outcome results